Jenna Sinopoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jenna Sinopoli has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jinru Shia
Memorial Sloan Kettering Cancer Center
62 shared publications - Kalyani Chadalavada
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
62 shared publications - Rona Yaeger
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
62 shared publications - Almudena Chaves Perez
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York
57 shared publications - Arnaud Da Cruz Paula
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
57 shared publications - Besnik Qeriqi
Memorial Sloan Kettering Cancer Center 1 New York, NY
57 shared publications
Latest Publications
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
RW7213 cell lines sequencing analysis
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
RW7213 cell lines sequencing analysis
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
C106 cell lines single cell sequencing analysis
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
C106 cell lines single cell sequencing analysis
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Patients Progression Cell Free DNA data
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Patients Progression Cell Free DNA data
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Generation of acquired resistance PDX model
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Generation of acquired resistance PDX model
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Patients Longitudinal Cell Free DNA data
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Patients Longitudinal Cell Free DNA data
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Characterization of acquired resistance in vitro models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Characterization of acquired resistance in vitro models
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
C106 resistant cells drug withdrawal and Patient #12 MSK-Impact data
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
C106 resistant cells drug withdrawal and Patient #12 MSK-Impact data
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Oncoprint of baseline alterations in CRC patients who developed resistance to KRAS G12C and EGFR inhibitors
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Oncoprint of baseline alterations in CRC patients who developed resistance to KRAS G12C and EGFR inhibitors
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Generation of acquired resistance PDX model
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer
Generation of acquired resistance PDX model